GLP-1s and mood: depression, anxiety and what the FDA review found

Reviewed 18 sourcesPublished by PepVault

Do Ozempic, Wegovy, Mounjaro or Zepbound cause depression? The FDA's 2026 review, the labels' warning removed, the trial rates against placebo, and what helps.

Woman in an olive jacket takes a slow walk on a sunlit forest path
Last reviewed
Sources
18
Questions
6
Compounds
3

The short answer

The FDA found no increased risk of depression, anxiety or suicidal thoughts on GLP-1 medicines. Its January 2026 review pooled 91 placebo-controlled trials with 107,910 people, and Wegovy, Zepbound and Saxenda dropped their suicidal-thoughts warning in February 2026. In the weight trials, depression and anxiety ran slightly lower on the drug than on placebo. New or worsening low mood is still worth a call to your prescriber.

Every number checked at its primary source · · 18 sources · How we research

Evidence: Strong for reassurance: an FDA meta-analysis of 91 placebo-controlled trials, two maker-funded pooled trial analyses that measured mood at every visit, and large observational studies. The trials mostly excluded people with serious psychiatric illness.

Woman in an olive jacket takes a slow walk on a sunlit forest path

Do GLP-1s cause depression or suicidal thoughts?

The FDA's answer, after the largest review yet, is no. GLP-1 medicines copy a gut hormone, GLP-1, that lowers blood sugar after a meal and acts in the parts of the brain that control appetite. In July 2023, after reports of suicidal thoughts in people taking them, the agency opened an investigation. Its first look, published in January 2024, found no evidence that these medicines cause suicidal thoughts or actions, but it could not rule out a small risk because the trials held so few events2.

So the FDA ran a bigger test. It pooled 91 placebo-controlled trials with 107,910 people (60,338 on a GLP-1 medicine, 47,572 on a placebo, a dummy treatment) and found no increased risk of suicidal thoughts or behaviour, and none for anxiety, depression, irritability or psychosis either. It also compared 2,243,138 people with type 2 diabetes in its Sentinel insurance-claims network who started a GLP-1 medicine or an SGLT2 inhibitor, another diabetes drug, and found no increase in self-harm on the GLP-1 side. On January 13, 2026 it asked the makers of Saxenda, Wegovy and Zepbound to remove the warning1.

Europe reached the same place earlier. In April 2024 the safety committee of the European Medicines Agency (PRAC), which had started with semaglutide and liraglutide and widened its review to the class, concluded that the evidence does not support a causal link with suicidal or self-injurious thoughts and actions, so no change to the product information was needed3.

If your mood feels different after starting or stepping up a dose, PepVault's daily check-in rates your mood beside energy and sleep, and the side-effect log keeps the symptom, its strength on a 1 to 5 scale, the date and a note. Log it in PepVault

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

If your mood feels different after starting or stepping up a dose, PepVault's daily check-in rates your mood beside energy and sleep, and the side-effect log keeps the symptom, its strength on a 1 to 5 scale, the date and a note.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What do the Ozempic, Wegovy, Mounjaro and Zepbound labels say now?

The weight-loss labels carried a warning; the diabetes labels never did. The warning was not built on GLP-1 data: until its February 2026 revision, Wegovy's label read "Suicidal behavior and ideation have been reported in clinical trials with other weight management products" and asked prescribers to watch for depression18. The FDA traces it to reports with a variety of older weight-loss medicines1. The current US labels, read on DailyMed in November 2026:

Label (medicine)Mood warning todayMood or sleep effects in its trial tables, drug against placebo
Ozempic (semaglutide, diabetes)Never had oneNone listed
Mounjaro (tirzepatide, diabetes)Never had oneNone listed
Wegovy (semaglutide, weight)Removed February 2026Adults: none listed. Teens (12 and older): anxiety 4% against 2%
Zepbound (tirzepatide, weight)Removed February 2026None listed
Saxenda (liraglutide, weight)Removed February 2026Adults: anxiety 2.0% against 1.6%, insomnia 2.4% against 1.7%. Teens: depression 4% against 2.4%

The tables list only effects reported more often on the drug than on placebo, at the labels' cut-off of 2% or more in adults and 3% or more in teens; the teen rows come from single trials of 201 teens (Wegovy) and 251 teens (Saxenda), where one or two people move a percentage46. Ozempic and Mounjaro list no mood effect at all78.

One mood line stays in all five labels, and it matters: the patient leaflets list anxiety, irritability or mood changes as signs of low blood sugar, a risk the labels say is higher when a GLP-1 is taken with insulin or a sulfonylurea45678. With those medicines, a sudden shaky, irritable spell is worth a glucose check before anything else.

How often did depression and anxiety show up in the trials?

Less often on the drug than on placebo. The makers' weight trials measured mood at every visit with two standard questionnaires: the PHQ-9, nine questions scored 0 to 27, where 0 to 4 means no or minimal depression, and the Columbia scale for suicidal thoughts. Pooled analyses of the semaglutide trials (STEP 1, 2 and 3) and the tirzepatide trials (SURMOUNT 1, 2 and 3) give these rates910:

MeasureSemaglutide 2.4 mg (Wegovy)PlaceboTirzepatide (Zepbound)Placebo
People in the pool2,1161,2612,8061,250
Any psychiatric side effect9.8%10.5%6.8%8.2%
Anxiety3.3%4.2%1.5%3.5%
Depression or depressed mood2.8%3.2%1.5%2.1%
Trouble sleeping3.4%3.6%2.9%2.3%
Suicidal thoughts on the Columbia scale1% or fewer1% or fewer0.6%0.6%
PHQ-9 score at the end (68 or 72 weeks)2.02.41.92.4

Across the semaglutide trials, 2.8% of people on the drug and 4.1% on placebo had a PHQ-9 score of 15 or more at some point after the start, the level that calls for a mental-health assessment9. On tirzepatide, 18.2% moved to a worse PHQ-9 band against 24.3% on placebo, and 52.4% moved to a better one against 41.8%10. The semaglutide analysis calls its drop in scores small and not clinically meaningful9: on both drugs, mood mostly held steady.

Who these numbers cover: the trials left out people with major depression in the past two years, a past suicide attempt, or severe illness such as schizophrenia or bipolar disorder, and both analyses were funded and co-written by the makers910. About one in five people in the tirzepatide pool had a past psychiatric diagnosis, and 7 to 9% took an antidepressant or a similar medicine10.

When do mood changes start on a GLP-1?

The trials found no stretch of weeks where mood turned bad on the drug. The STEP trials checked mood at weeks 12, 20, 36, 52 and 68, the SURMOUNT trials at weeks 12, 24, 36, 48, 60 and 72 plus four weeks after the last dose910. In the STEP trials, average scores rose a fraction in both groups through week 52 and stayed in the no-or-minimal range; by the end they sat lower on semaglutide9. In the SURMOUNT trials, scores fell more on tirzepatide than on placebo at every visit10.

What does change during the dose climb, called titration, is the body. Tiredness ran 11% on Wegovy against 5% on placebo, and 5 to 7% on Zepbound against 3%, and nausea is the most common effect of all, which Zepbound's label says comes mostly during the dose climb and eases over time45. A run of tired, queasy days can weigh on how a week feels, which is a reason to look at food, fluids and sleep before reading it as depression.

Stopping may be a different moment. A 2026 cohort study of people with type 2 diabetes in Shanghai hospital records found the risk of depression and anxiety disorders neutral or lower while they took a GLP-1, but higher after they stopped it than after stopping other diabetes drugs, and its authors single out anxiety; it is observational, so it shows a link rather than a cause17.

Commonly reported: quieter food thoughts and less guilt around eating, which many users describe as a lift in mood; and, for some, a flat, low-energy day or two after a dose step, which users tend to tie to eating much less.

What did the big real-world studies find?

Independent researchers found the same or lower risk: one pooled 27 placebo-controlled trials, and four observational studies followed real patients' records rather than assigning a drug, comparing people who started a GLP-1 with people on another treatment for the same condition. A hazard ratio below 1 means fewer events on the GLP-1 side:

StudyWhoWhat it found
Ebrahimi 2025, 27 placebo-controlled trials59,396 adults with diabetes or obesitySuicide-related events 0.047 against 0.042 per 100 person-years; no difference (rate ratio 0.76)11
Ueda 2024, Sweden and Denmark registers124,517 GLP-1 starters against 174,036 SGLT2 starters, mostly type 2 diabetesSuicide death 0.23 against 0.18 per 1,000 person-years (not significant); self-harm or suicide hazard ratio 0.83; new depression or anxiety 1.0112
Wang 2024, US health records240,618 people with overweight or obesityNew suicidal thoughts on semaglutide against other weight-loss drugs: hazard ratio 0.2713
Yu 2025, US health records16,321 matched pairs with overweight or obesitySuicidal thoughts or attempts on tirzepatide against other weight-loss drugs: 17 against 33 people, hazard ratio 0.5214
Liu 2026, US health records9,222 matched pairs of teens with obesitySuicide-related events on semaglutide, liraglutide or tirzepatide against lifestyle care: hazard ratio 0.74; no difference for depression, and none against metformin15

One study pointed the other way. A 2024 analysis of the World Health Organization's database of suspected side effects found 45% higher odds of suicidal thoughts being reported with semaglutide than with all other drugs (a reporting odds ratio of 1.45)16. That kind of study counts reports sent in, not people at risk, so news coverage and who gets prescribed a drug move it; its own authors called for urgent clarification, and the FDA's later trial pool and Sentinel study are the larger tests of the question1. The FDA's verdict on the published studies as a whole: they do not support a causal link1.

What helps if your mood dips on a GLP-1?

  1. Write it down the day it happens: what you feel, how strong, and how many days since your last dose or dose step.
  2. If you also take insulin or a sulfonylurea and feel shaky, sweaty or suddenly irritable, check your blood sugar first: the labels list mood changes as a sign of low blood sugar47.
  3. Look at the basics of the week: how much you ate, protein, fluids and sleep. A large drop in food can feel like a drop in mood.
  4. Tell your prescriber about new or worsening low mood, anxiety or any unusual change in mood or behaviour; the FDA asks patients to do exactly that1.
  5. The FDA's advice to patients is to keep taking the medicine as prescribed and to discuss any concern with their prescriber1, and not to stop on their own2. Whether to change the dose, pause or switch is your prescriber's decision.
  6. If you have depression or another mental-health condition already, tell your prescriber before you start, since the trials mostly left those patients out910.

PepVault's doctor's report shows your weekly mood trend from the check-in and lists each side effect you logged on the protocol, with its date and strength, so your prescriber sees the pattern in one place instead of from memory. Log it in PepVault

When to get help Thoughts of harming yourself are a reason to get help now, whatever the cause: in the US call or text 988, the Suicide and Crisis Lifeline, or your local emergency number elsewhere1.

Track it in the app

Sources

  1. US Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. Drug Safety Communication, January 13, 2026. fda.gov
  2. US Food and Drug Administration. Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. Drug Safety Communication, January 11, 2024. fda.gov
  3. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 8-11 April 2024. ema.europa.eu
  4. Wegovy (semaglutide) injection and tablets, US prescribing information. Novo Nordisk. DailyMed, version 19, June 2026. dailymed.nlm.nih.gov
  5. Zepbound (tirzepatide) injection, US prescribing information. Eli Lilly. DailyMed, version 40, September 2026. dailymed.nlm.nih.gov
  6. Saxenda (liraglutide) injection, US prescribing information. Novo Nordisk. DailyMed, version 22, June 2026. dailymed.nlm.nih.gov
  7. Ozempic (semaglutide) injection, US prescribing information. Novo Nordisk. DailyMed, version 20, June 2026. dailymed.nlm.nih.gov
  8. Mounjaro (tirzepatide) injection, US prescribing information. Eli Lilly. DailyMed, version 40, September 2026. dailymed.nlm.nih.gov
  9. Wadden TA et al. Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials. JAMA Intern Med. 2024. PubMed 39226070
  10. Wadden TA et al. Psychiatric safety of tirzepatide in people with obesity and no known major psychopathology: a post hoc analysis of SURMOUNT. Obesity (Silver Spring). 2026. PubMed 41537305
  11. Ebrahimi P et al. Suicide and self-harm events with GLP-1 receptor agonists in adults with diabetes or obesity: a systematic review and meta-analysis. JAMA Psychiatry. 2025. PubMed 40105856
  12. Ueda P et al. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med. 2024. PubMed 39226030
  13. Wang W et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024. PubMed 38182782
  14. Yu WS et al. Association of tirzepatide and the risk of suicide in a real-world cohort. Front Psychiatry. 2025. PubMed 41334076
  15. Liu TH et al. Psychiatric safety of GLP-1 and dual GIP/GLP-1 receptor agonists in adolescents with obesity. Diabetes Obes Metab. 2026. PubMed 42736027
  16. Schoretsanitis G et al. Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality. JAMA Netw Open. 2024. PubMed 39163046
  17. Zhang T et al. Association of GLP-1RA discontinuation and risk of depressive and anxiety disorders in people with type 2 diabetes: a cohort study. Nat Metab. 2026. PubMed 42426287
  18. Wegovy (semaglutide) injection and tablets, US prescribing information, section 5.10 (before its removal). Novo Nordisk. DailyMed archive, version 14, revised December 2025, published January 2026. dailymed.nlm.nih.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo